Benefits
Body Weight, Waist, and BMI Reduction
In one 120-day placebo-controlled trial in obese, slightly dyslipidemic pre-menopausal women, yacon syrup at 0.14 g FOS/kg/day was followed by decreases in body weight, waist circumference, and BMI. This is a single trial in one specific group of women, so it does not show what yacon syrup would do for someone who is not obese or not insulin resistant.
Insulin Resistance Improvement
In the same 120-day trial, women who started with raised insulin resistance had lower fasting insulin and a lower HOMA-IR score (a calculation used to estimate insulin resistance). Fasting blood sugar did not change. Neither study cited on this page measured GLP-1 or any other gut hormone, so the reason for the insulin change was never established.
LDL Cholesterol Reduction
In the 120-day trial in obese pre-menopausal women, LDL cholesterol fell, while total cholesterol and triglycerides did not change significantly. A 2025 systematic review of seven small trials with 161 participants in total also reviewed blood fats, but its authors flagged small sample sizes and differing doses and called for larger studies.
Increased Defecation Frequency and Satiety
Trial data documented increased defecation frequency and satiety sensation with yacon syrup. FOS is a fermentable fiber, and fuller feelings and more regular bowel movements are common with fibers of this kind. GLP-1, PYY and other appetite hormones were not measured in either study cited here, so no hormone explanation has actually been tested for yacon syrup.
Prebiotic / Gut Microbiome Support
FOS is fermented by gut bacteria such as Bifidobacterium and Lactobacillus, the same general behavior seen with inulin and other fructan fibers. That comes from fiber research in general rather than from bacterial measurements in the two studies cited on this page. A systematic review noted improvements in intestinal transit and gut microbiota across yacon trials.
Mechanism of action
Fructooligosaccharide (FOS) Prebiotic Effect
Yacon syrup is high in inulin-type FOS (40 to 70 percent of dry weight), which makes it one of the richer plant sources. FOS is not broken down by human digestive enzymes and is instead fermented by gut bacteria, producing short-chain fatty acids (acetate, propionate, butyrate). The metabolic and anti-inflammatory effects attributed to those fatty acids come from wider fiber research and were not measured in either yacon study cited on this page.
A Gut Hormone Idea That Has Not Been Tested for Yacon
One proposed explanation is that short-chain fatty acids from fiber fermentation prompt gut cells to release appetite and blood sugar hormones such as GLP-1 and PYY. This idea is borrowed from wider fiber research. Neither of the two studies cited on this page measured GLP-1, PYY or any other gut hormone, so it stays an untested hypothesis for yacon syrup.
Reduced Caloric Density (Low-Glycemic Sweetener)
FOS provides ~1.5-2 kcal/g vs. ~4 kcal/g for sucrose — and most of those calories come from colonic SCFAs that are partially used by gut bacteria. Swapping it in for sugar therefore adds fewer usable calories, though yacon syrup still contains real sugars and counts toward carbohydrate intake, and fasting blood sugar did not change in the trial cited here.
Bulk Stool Formation and Transit
Like other soluble fibers, FOS adds water-binding bulk to stool and may accelerate colonic transit. This may explain the more frequent bowel movements reported in the trial cited here.
Modest Mineral Absorption Enhancement
FOS may modestly enhance calcium and magnesium absorption via colonic SCFA-induced mineral solubilization. Any such effect is likely small, and it has not been shown for yacon syrup in either study cited on this page. Nothing about bone health has been tested here.
Clinical trials
Double-blind, placebo-controlled trial. Two doses of yacon syrup (0.29 g and 0.14 g FOS/kg/day) vs. placebo for 120 days in obese pre-menopausal women. Anthropometric measurements, blood glucose, calcium, lipid and insulin concentrations, HOMA-IR. (Genta, Cabrera, Habib, Pons, Carillo, Grau, Sánchez 2009, Clin Nutr)
Obese, slightly dyslipidemic pre-menopausal women with baseline insulin resistance (HOMA-IR > 2.70).
Recommended dose without GI side effects: 0.14 g FOS/kg/day. Significant decreases in body weight, waist circumference, and BMI. Significant decreases in fasting serum insulin and HOMA-IR. Significant LDL cholesterol reduction. Increased defecation frequency and satiety sensation. Fasting glucose unchanged. Higher dose (0.29 g/kg) caused GI side effects. This is a single trial in one narrow group of women, with no participant count reported here. Gut hormones such as GLP-1 were not measured. The results have not been repeated in a large independent trial.
PRISMA-compliant evidence review of yacon syrup clinical trials over the last decade. Searched Medline (PubMed), Science Direct, Embase, Scopus, SciELO through. Inclusion: clinical trials of yacon syrup on glycemic control, lipid profile, insulin sensitivity, appetite regulation, gut microbiota in healthy/overweight/obese individuals. (Nutrients)
7 clinical trials included, totaling 161 participants from diverse populations.
The review reported that across the included trials yacon syrup was associated with lower fasting insulin, lower HOMA-IR and lower LDL cholesterol, along with better reported fullness and bowel transit. The seven trials together included only 161 people, and the authors flagged small sample sizes and differing doses and called for larger trials. The review covered blood sugar control, blood fats, insulin sensitivity, appetite and gut bacteria; it did not assess GLP-1 or any other gut hormone.
Randomized, double-blind, placebo-controlled clinical trial of yacon flour vs. placebo in overweight adults. Outcomes: body composition, intestinal function. (Machado, da Silva, Chaves, Clin Nutr ESPEN)
Overweight adults.
This study is reported as finding better body composition and bowel function with yacon flour than with placebo. It tested yacon flour rather than yacon syrup, no participant count or dose is given, and it is not one of the two references listed at the bottom of this page, so it has not been checked against the published record.